Regeneron Pharmaceuticals reported its financial results for the full year ended December 31, 2025. Dupixent and Kevzara net product sales reached USD 18.38 billion for the period. Regeneron's share of collaboration profits from commercialization of antibodies related to these products amounted to USD 6.17 billion, with the company's share of profits representing 29 percent of Dupixent and Kevzara net product sales. After accounting for reimbursement of development expenses to Sanofi, Regeneron's share of profits was USD 5.24 billion. EYLEA 8 mg and EYLEA net product sales outside the United States totaled USD 1.35 billion, with Regeneron's share of profits at USD 1.28 billion, reflecting 37 percent of EYLEA sales outside the United States. The company noted that the decrease in its share of profits for EYLEA sales outside the United States during 2025 was primarily driven by lower sales of the product in these markets. Regeneron also highlighted ongoing substantial costs related to commercialization of marketed products and expansion of research and development efforts. The company’s financial results are influenced by product net sales, research and development progress, timing of expenses, the continuation of collaborations—particularly with Sanofi and Bayer—and income tax expenses based on profits or losses in different countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000872589-26-000008), on February 04, 2026, and is solely responsible for the information contained therein.